6-Hydroxybenzbromarone

Modify Date: 2024-01-14 22:53:52

6-Hydroxybenzbromarone structure	Common Name	6-Hydroxybenzbromarone
	CAS Number	152831-00-0	Molecular Weight	440.08300
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₇H₁₂Br₂O₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of 6-Hydroxybenzbromarone

6-Hydroxybenzbromarone is the major metabolite of Benzbromarone with a longer half-life and greater pharmacological potency than the parent compound. 6-Hydroxybenzbromarone is a protein Eyes Absent 3 (EYA3) inhibitor with an IC50 value of 21.5 μM. 6-Hydroxybenzbromarone is an angiogenic agent, has strong inhibitory effects on cell migration, tubulogenesis, and angiogenic sprouting[1].

Name	6-Hydroxybenzbromarone
Synonym	More Synonyms

Description	6-Hydroxybenzbromarone is the major metabolite of Benzbromarone with a longer half-life and greater pharmacological potency than the parent compound. 6-Hydroxybenzbromarone is a protein Eyes Absent 3 (EYA3) inhibitor with an IC50 value of 21.5 μM. 6-Hydroxybenzbromarone is an angiogenic agent, has strong inhibitory effects on cell migration, tubulogenesis, and angiogenic sprouting[1].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphatase
Target	IC50: 21.5 μM (EYA3); metabolite[1]
In Vitro	6-Hydroxybenzbromarone (7.5 μM; 72 hours) shows over 50% reduction in cell proliferation. Meanwhile, treatment with BBR and BZ also reduces cell viability, but none of the other compounds tested has a negative impact on cell viability or proliferation[1]. 6-Hydroxybenzbromarone (7.5 μM; 1-20 hours) has inhibitory affects EC migration tubulogenesis of HUVECs. However, the effect of 6OH-BBR on tube formation is attenuated in the presence of high concentrations of fetal bovine serum (FBS), likely reflecting non-specific protein binding[1]. Cell Proliferation Assay[1] Cell Line: HUVEC cells Concentration: 7.5 μM Incubation Time: 72 hours Result: Inhibited HUVEC cells proliferation.
References	[1]. Pandey RN, et al. Structure-activity relationships of benzbromarone metabolites and derivatives as EYA inhibitory anti-angiogenic agents.PLoS One. 2013 Dec 18;8(12):e84582.